Diabetic Macular Edema

Diabetic retinopathy can cause swelling of the center of the retina, the macula, and vision loss.

What is a Diabetic Macular Edema

Diabetic macular edema is swelling in the retina associated with diabetes. This swelling can blur and distort the vision. The swelling occurs because the walls of the small blood vessels are progressively more damaged in diabetes, and there is leakage of blood and fluid into the cells of the retina. There are a variety of options to treat diabetic macular edema. The oldest treatment is laser for retinal swelling. It has been studied for decades and has been shown to be safe and effective. As with all treatments, it is not curative, and it is not without risk, but laser is one of the safest things that we do in diabetic retinal care. Other newer treatments for diabetic retinal swelling have been shown to improve vision even more than laser in some cases, and have also been shown to be safe and effective in large modern trials. These treatments are a variety of injections given into the eye in the office, and they are sometimes given alone and sometimes given with laser in addition. There are two major classes of injections used in diabetic macular edema, and those are small molecule injections and corticosteroid injections. The injections work in different ways to reduce the leakage and swelling in the retina, and sometimes the different types of injections are both used. The injections are administered under local anesthesia, and are often relatively well-tolerated by patients. Injections are also amongst the safest procedures performed in the retinal clinic, and the specific risks and benefits of injections will be discussed by your doctor. Most patients with blurred vision from diabetic macular edema enjoy an improvement in vision with treatment. Often, treatment to maintain vision is ongoing, and the long-term treatment plan is individualized to each specific patient in our practice.

What is a Laser?

When diabetic macular edema is caused by focal areas of leakage, laser treatment can be helpful. Studies were done in the 1980's validating the use of laser to reduce the risk of vision loss and improve vision in patients with diabetic macular edema. The advantage of laser of intravitreal injections is that laser treatment usually only needs to be repeated a few times. Intravireal injections are given monthly. The disadvantage of laser, is that it does not improve vision as much as intravitreal injections do when the center of the macula is swollen. Many physicians will use both laser and intravitreal injections depending on the area of the macula that is swollen and the findings on examination and testing.

Lucentis for Diabetic Macular Edema

Monthly Lucentis therapy is helpful for patients with diabetic macular edema. With laser only, about 15 percent of patients have substantial visual improvement at 2 years. With Lucentis therapy, about 40 percent of patients have a substantial improvement in visual acuity. Subsequent studies have shown that ongoing monthly treatment is usually not necessary to maintain the visual benefit.


Diabetic Macular Edema NEWS

Below are current articles from a Google News Feed on Diabetic Macular Edema

Role of peripheral pan-retinal photocoagulation in diabetic macular ed | OPTH  Dove Medical Press

Ahmad M Mansour,1,2 Khalil El Jawhari,3 J Fernando Arevalo4 1Department of Ophthalmology, American University of Beirut, Beirut, Lebanon; 2Department of ...

Deep Learning Models Could Boost DME Diagnosis Efficiency  MD Magazine

The best way to diagnose diabetic macular edema is using optical coherence tomography, but it is costly.

Ultra widefield fluorescein angiography in diabetic macular edema | American Journal of Ophthalmology  MD Linx

Internal Medicine Article: Classification of regions of nonperfusion on ultra-widefield fluorescein angiography in patients with diabetic macular edema.

Experimental drug delivers one-two punch to vision loss: Experiments show new therapy slows blood vessel leakage associated with diabetic macular edema and macular degeneration  Science Daily

In studies with lab-grown human cells and in mice, researchers have found that an experimental drug may be twice as good at fighting vision loss as previously ...

Ripasudil Treatment for Patients with DME and Glaucoma  MD Magazine

One month after ripasudil treatment, investigators saw the mean foveal thickness decrease significantly and noted decreases in intraocular pressure.

Difference in Treatment Effect Between Intravitreal Aflibercept Injection and Laser by Baseline Factors in Diabetic Macular Edema  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To evaluate the effect of baseline factors on differences in vision gains with ...

Allergan eye drug fails to impress on safety, upping pressure ahead of key meeting  BioPharma Dive

Allergan on Tuesday disclosed new safety results for an experimental eye drug, abicipar, but a modest improvement in a key inflammation rate failed to convince ...

Global Diabetic Macular Edema Market Forecast & Growth Opportunities 2019 | Alimera Sciences Inc, Regeneron Pharmaceuticals Inc, Pfizer Inc.  People Herald Today

This Latest comprehensive report on global Diabetic Macular Edema market 2019-2025 enables customers to evaluate the predicted future sales in several ...

Study Explores Efficacy of Iluvien Implant Efficacy Over 3 Years  MD Magazine

Retrospective study assesses real-world outcomes of treating patients with chronic DME with Iluvien implant.

Social cost of retinal blindness in US will be billions of dollars by 2020  Healio

FORT LAUDERDALE, Fla. — The direct, indirect, and intangible costs due to neovascular age-related macular degeneration, diabetic macular edema, and ...

Possible New Drug May Help Combat Vision Loss  Bel Marra Health

A new experimental drug may be able to combat vision loss. The study was conducted on lab-grown human cells and mice by Johns Hopkins researchers.

Study Shows Aflibercept Could Impact Endothelium Thickness  MD Magazine

Investigators found that intravitreal administration of aflibercept might alter the corneal endothelium within 6 months of their first injection.

AJMC® in the Press, March 29, 2019  AJMC.com Managed Markets Network

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

Suprachoroidal drug delivery shows benefits for DME treatment  Healio

FORT LAUDERDALE, Fla. — Suprachoroidal drug delivery is a novel approach that targets posterior tissues, minimizes exposures to the anterior segment and ...

Study Shows that Using AI in Eye Screenings Could Help Improve Vision Outcomes  Medical Device and Diagnostics Industry

A new study published in Investigative Ophthalmology & Visual Science suggests that artificial intelligence (AI) could be used to provide widespread, ...

Oxurion NV announces full enrollment of its Phase 2 trial evaluating efficacy and safety of the combination of anti-PlGF (THR-317) and anti-VEGF (ranibizumab) for treatment of DME, ahead of schedule  Associated Press

Press release *content* from Globe Newswire. The AP news staff was not involved in its creation.

Battered and out of options, Histogenics turns to eye drug developer Ocugen for reverse merger  Endpoints News

Microcap company Histogenics has managed to stir up a final rally around its stock before it's relegated to the biotech history books. Malvern, PA-based Ocugen, ...

Non Infectious Macular Edema Treatment Market to Showcase Healthy Expansion at 7.0% CAGR During 2020  New Daily Herald

The ophthalmology sector has gained massive traction during the course of the last few years. This is a result of growing prevalence of diseases like macular ...

MAPLE trial shows less intraocular inflammation after abicipar use  Healio

There was a decrease in the incidence of intraocular inflammation in the 28-week MAPLE study of abicipar pegol, Allergan and Molecular Partners announced ...

Do you experience flashes of light, distortion of images, cloudy vision? Screening for retinal diseases early can be beneficial  Economic Times

It is important for everyone to detect drop in vision at the earliest stage.

Macular Edema Treatment Market Size Archives  TechnoBleak

Macular Edema Treatment Market 2018 Opportunities, Competition from Opponents, Dynamics, Demand, Challenge and Risk and Forecast to 2026.

Regenxbio (RGNX) Appoints Dr. Steve Pakola as CMO  StreetInsider.com

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. REGENXBIO Inc. (Nasdaq: RGNX), a leading ...

Diabetic Eye Testing Market 2026: Top Key Players Novarand, Heidelberg Engineering, Inc.  Amazing Newspaper

Diabetic eye disease comprises a group of eye-related problems that affect people with diabetes. Eye examination provides the effective clue for detecting ...

Diabetic Macular Edema Market Growing Adoption of Technology will Spur Growth of the US$ Million in 2017 – 2027  New Daily Herald

Market Insights forecasts the global diabetic macular edema market to grow from nearly US$ 3,710 Mn in 2017 to over US$ 4,100 Mn by 2027 end.

Oxurion completes phase 2 enrollment for anti-PlGF, anti-VEGF combination therapy for DME  Healio

Enrollment is complete in a phase 2 trial of the anti-PlGF THR-317 in combination with the anti-VEGF ranibizumab for the treatment of diabetic macular edema, ...

Experimental drug 'slows down macular degeneration'  Spectator.co.uk

An experimental drug may be twice as good at fighting vision loss as previously thought, according to new research by Johns Hopkins Medicine. The new…

Patients treated with aflibercept experienced greater improvements in NPDR  Healio

FORT LAUDERDALE, Fla. — The proportion of patients with a 2 or more-step improvement in non-proliferative diabetic retinopathy scores was significantly ...

Diabetic Macular Edema Market Revenues Projected to be Accounted US$ 4,100 Mn by 2027  dailychronicle24.com

The global diabetic macular edema (DME) market is projected to register a sluggish expansion at 1.1% CAGR through 2027, according to a report by Future ...

Macular Edema Treatment Market trends Archives  Business Herald

Macular edema is the condition characterized by abnormal leakage and accumulation of fluid that forms blister in the layer of macula. The macula is an ...

Global Diabetic Macular Edema Drug Market: Key companies Profile, their market Share and other important parameters  Market Research Publisher

Global Diabetic Macular Edema Drug Market offers a wide range of market dynamics like current trends (2019), estimated forecast (2025), segmentation by ...

Macular Edema Treatment Market  TechZiffy

Macular Edema Treatment Market 2026: Top Companies, Regional Growth Overview and Growth Factors Details by Regions, Types and Applications.

Global Diabetic Macular Edema Drug Market Insights Report 2019-2024 : Manufacturers, End Users, Future Outlook and Prospects for The Market 2024  Healthcare Industry

Diabetic Macular Edema Drug Market report provides in-depth information about Diabetic Macular Edema Drug industry with a market overview, top vendors, ...

Roche Study Shows AI Can Detect Severity of Diabetic Macular Edema  BioSpace

The study showed that artificial intelligence can be used to provide widespread, cost-effective eye screenings via telemedicine to assist ophthalmologists in ...

Kodiak Sciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights  BioSpace

Published: Mar 28, 2019. PALO ALTO, Calif., March 28, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company ...

Allergan to resume marketing of macular edema treatment  Korea Biomedical Review

Allergan Korea said Tuesday that it has started re-marketing Ozurdex (ingredient: dexamethasone), a steroid eye implant for macular edema.

Characteristics of diabetic macular edema on optical coherence tomogra | OPTH  Dove Medical Press

Characteristics of diabetic macular edema on optical coherence tomography may change over time or after treatment Shwu-Jiuan Sheu,1,2 Ying-Yen Lee,1 ...

Artelus is using AI to save people from going blind. Here's how  YourStory

Rajarajeshwari Kodhandapani has a dream – to screen one million people for diabetic retinopathy (DR) so they can get timely treatment and not risk going blind.

Global Macular Edema Therapeutics Market Insights Report 2019-2024 : Allergan, Novartis, Roche, Regeneron Pharmaceuticals, Pfizer, Bayer  Industry News Updates USA

The “Macular Edema Therapeutics Market” worldwide is among the most budding markets. This overall market is growing with an impelled rate and ...

FDA accepts Outlook Therapeutics' IND for ONS-5010  Seeking Alpha

The FDA accepts Outlook Therapeutics' (OTLK) IND application for ONS-5010, an innovative monoclonal antibody (mAb) therapeutic product candidate being ...

Treatment patterns in diabetic macular edema in Taiwan: a retrospectiv | OPTH  Dove Medical Press

Treatment patterns in diabetic macular edema in Taiwan: a retrospective chart review Shwu-Jiuan Sheu,1,2 Cheng-Kuo Cheng,3,4 Hsi-Kung Kuo,5 Ching-Yao ...

Risuteganib complements anti-VEGF treatment for diabetic macular edema  Healio

VIENNA — Integrin inhibitor risuteganib was effective in complementing the anti-VEGF pathway when administered sequentially to an anti-VEGF drug in patients ...

Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Aaron Osborne, MBBS MRCOphth, as Chief Medical Officer  Associated Press

Press release *content* from Globe Newswire. The AP news staff was not involved in its creation.

Global Diabetic Macular Edema Drug Market Growth 2019 |2024 Industry Status and Outlook.  Market Reports

Global Diabetic Macular Edema Drug Market Growth Analysis, Share, Demand by Regions, Types and Analysis of Key Players- Research Forecasts to 2024.

Anti-VEGF Effective in Persistent Diabetic Macular Edema  Medscape

A recent analysis associated three different anti-VEGF agents with meaningful vision gains through 2 years of follow-up.

CPAP for OSA Does Not Improve Diabetic Macular Edema or Visual Acuity  Pulmonology Advisor

Continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea (OSA) in patients with type 2 diabetes mellitus (T2DM) and diabetic macular ...

Global Retinal Disorders Treatment Market Industry: A Latest Research Report to Share Market Insights and Dynamics  Industrial Journalism

Global Retinal Disorders Treatment Market offers a wide range of market dynamics like current trends (2019), estimated forecast (2025), segmentation by types, ...

Alimera Sciences wins Health Canada nod for diabetic macular edema implant  Mass Device

Alimera Sciences (NSDQ:ALIM) said last month that it won approval in Canada for its intravitreal implant designed to treat diabetic macular edema. The Iluvien ...

Retinal Biologics Market to Grow at 10.7% in 2019: FMI Study  PharmiWeb.com

VALLEY COTTAGE, N.Y. – Retinal biologics market value surpassed US$ 14.6 billion in 2018 and projected to grow at 10.7% y-o-y in 2019, as per a new FMI ...

Diabetic Macular Edema Treatment Market Research Analysis 2019-2025 includes Product Category, Application and Specification  The Akron Observer

Diabetic Macular Edema Treatment Market report provides complete evaluation for those who are looking for Business expand in various regions, manufacturers ...

Global Macular Edema Therapeutics Market 2019 – 25 Roche, Bayer, Allergan, Regeneron Pharmaceuticals, Novartis  Market Research Gazette

Global Macular Edema Therapeutics Market research report is an in-depth and a professional document that provides a comprehensive overview of the market.

2018-2022 Diabetic Macular Edema Treatment Market Forecasting Report According to Top Players, Regions | Research Analysis, Market Future Scope & Trends with Expected CAGR at 1.45%  Flatland Today

Diabetic Macular Edema Treatment report provides detailed analysis and competitive analysis by region and other main information like a manufacturing ...

Case Report on DME | Medpage Today  MedPage Today

An unexpected resolution of diabetic macular edema.

Non Infectious Macular Edema Treatment Market to reach a valuation of over US$ 17200 Mn by the end of 2026.  New Daily Herald

The ophthalmology sector has gained massive traction during the course of the last few years. This is a result of growing prevalence of diseases like macular ...

Global Ocular Drug Delivery Technology Market Technological Breakthroughs Analysis in Next Few Years, 2019-2025  Market Research Gazette

In 2018, the global Ocular Drug Delivery Technology market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of ...

KalVista To Pioneer Plasma Kallikrein Inhibitor Therapy For Diabetic Macular Edema  Seeking Alpha

Anti-VEGF therapy for diabetic macular edema (DME) is heralded as a miracle treatment. Granted, but there exists a significant subset of minimally- or ...

PhotoOpTx Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Network  PR Web

Diabetic macular edema (DME) is the most common condition that contributes to vision loss in persons with diabetes. PhotoOpTx, LLC has entered into an ...

Alimera Sciences (ALIM) Announces Approval Received in Mutual Recognition Procedure for New Indication for ILUVIEN in Europe  StreetInsider.com

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

The efficacy and safety of aflibercept and conbercept in diabetic macu | DDDT  Dove Medical Press

The efficacy and safety of aflibercept and conbercept in diabetic macular edema Siwei Cai, Qianhui Yang, Xiaorong Li, Yan Zhang Tianjin Medical University ...

Diabetic Macular Edema Market 2019 Global Industry Trends, Size, Segments, Competitors Strategy, Regional Analysis, Review, Key Players Profile, Statistics and Growth to 2023 Analysis  Mcallen Post

Diabetic Macular Edema Market 2019 Global Industry report covers the latest market statistics, industry growth driving factors, size, share, trends, as well as ...

Relationship Between Dry Retinal Volume and Visual Acuity in Diabetic Macular Edema  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To evaluate the relationship between a novel spectral-domain optical ...

Vision Care Market – Performance Survey 2028 | Johnson & Johnson, Valeant Pharmaceuticals  Amazing Newspaper

Global Vision Care Market: Overview. An upcoming report on the global vision care market by TMR Research could be a valuable source of information for major ...

BLOG: Laser still has an important role in diabetic eye disease  Healio

Ophthalmology Blogs | Mali | There is no question that the introduction of anti-VEGF agents has dramatically changed the landscape of how surgeons approach ...

FDA declines to approve pre-filled syringe version of Regeneron's Eylea  Reuters

(Reuters) - Regeneron Pharmaceuticals Inc said on Thursday the U.S. Food and Drug Administration declined to approve a pre-filled syringe version of its ...

Single Retinal Layer Changes After Subthreshold Micropulse Yellow Laser in Diabetic Macular Edema  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | A pilot prospective, interventional study has been conducted on 10 patients with diabetic macular edema ...

Implantable Drug Delivery Devices Market Size Archives  Business Herald

According to a report by World Health Organization (WHO), 2017, chronic diseases are the major cause of disabilities worldwide. The estimated global burden ...

Google launches India program to screen diabetics for eye conditions that can cause blindness  CNBC

Google and Verily teamed up to develop a screening tool for conditions that can cause preventable eye disease in adults. It is now being used at an eye hospital ...

Patrik De Haes, MD: What's Coming Down the Retina Pipeline  MD Magazine

An anti-PIGF, a plasma kallikrein inhibitor, and a pan RGD integrin antagonist are some of the investigational treatments in the pipeline for diabetic retinopathy ...

Trends in Diabetic Macular Edema Drug Market 2023 by Investment Feasibility, Sales, Production and Company Introduction  RISReport

The Global Diabetic Macular Edema Drug Market covers a complete market structure across the world with the detailed analysis of major key factors. This report ...

ICO Publishes New Guidelines for Diabetic Retinopathy  MD Magazine

Importantly, they are not directed toward ophthalmologists, but at general physicians and public healthcare professionals.

Significant Product Pipeline and Emerging Opportunity in Biosimilars Trending the Non-Infectious Macular Edema Treatment Market  Titan Chronicle

The ophthalmology sector has gained massive traction during the course of the last few years. This is a result of growing prevalence of diseases like macular ...

One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium  BioSpace

Published: Feb 09, 2019. TARRYTOWN, N.Y., Feb. 9, 2019 /PRNewswire/ --. Trial showed that early intervention with EYLEA improved diabetic retinopathy ...

Vision Care Market – Insights On Future Scope 2028 | Novartis, ZEISS  Market Research Gazette

Global Vision Care Market: Overview. An upcoming report on the global vision care market by TMR Research could be a valuable source of information for major ...

One in four anti-VEGF therapy patients with DME lost to follow-up  Healio

A quarter of patients with diabetic macular edema who received an anti-VEGF injection to treat nonproliferative diabetic retinopathy did not return for a follow-up ...

Eylea's PANORAMA data give fuller view of efficacy in label expansion bid  BioPharma Dive

Significantly fewer patients with advanced forms of a diabetic eye disease experienced vision-threatening events when taking Regeneron Pharmaceuticals' ...

It’s smaller than a grain a rice and it’s helping reverse vision loss for diabetics  11Alive.com WXIA

ATLANTA — Think about a bag of rice. Focus on one tiny grain. Got the image? Good. Now, imagine something smaller than that singular piece of rice, being ...

VIDEO: Allegro updates progress of Luminate for DME  Healio

CHICAGO — At the Ophthalmology Innovation Summit at AAO, Vicken Karageozian, MD, CEO of Allegro Ophthalmics, discusses the progress of Luminate for ...

FDA to Review Injection Treatment for Diabetic Retinopathy  Pharmacy Times

The FDA has accepted for review Regeneron Pharmaceuticals' supplemental Biologics License Application (sBLA) of aflibercept (EYLEA Injection) to treat ...

Google, Verily using AI to screen for diabetic retinopathy in India  Healthcare IT News

The machine learning algorithm can also help with screening for diabetic macular edema, a boon for patients in a country where physicians are in short supply.

Anti-VEGF Efficacy in DME: Early Response Is Not Destiny  Medscape

New data from Protocol T shows that eyes with poor 12-week response often had good vision at 2 years without switching therapies.

Phase 3 trials to focus on Port Delivery System for AMD, faricimab for DME  Healio

Genentech and Roche announced the initiation of three large phase 3 clinical trials evaluating the Port Delivery System with ranibizumab to treat wet ...

Aflibercept Benefits Bevacizumab-Unresponsive Diabetic Retinopathy Patients  MD Magazine

A new analysis of an ongoing clinical study offers insights for treating retinal vein occlusion in poor responders to bevacizumab.

Integrin Beta 3 Market | Global Research Insight 2018-2023  TheCells

Global Integrin Beta 3 Insight. Get industry insights and important projections for the market in upcoming quarters with the Global Integrin Beta 3 Research report ...

Frequency of Bevacizumab and Ranibizumab Injections for Diabetic Macular Edema in Medicare Beneficiaries  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To describe the frequency and variation of intravitreal bevacizumab ...

Switching to Aflibercept from Ranibizumab Improved DME Outcomes  MD Magazine

Patients with diabetic macular edema (DME) switching to aflibercept from ranibizumab improved their BCDA by an average of 5 letters over 9-12 months.

OPT-302 Improves Acuity in Combination with Aflibercept  MD Magazine

Patients with diabetic macular edema who do not show sufficient progress after anti-VEGF-A treatment may soon have a new option.

Key Anti-VEGF Therapies Have Big Advantages and Drawbacks  MD Magazine

A new review of literature about 2 anti-VEGF therapies for diabetic macular edema suggest the drugs hold promise, but not without some caveats.

The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide | IMCRJ  Dove Medical Press

The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with ...

Statins May Reduce Risk of Retinopathy in Diabetes Patients  MD Magazine

Statins are already a common therapy among patients with type 2 diabetes. Its cholesterol-lowering benefits may help retain patient vision longer.

Diabetic Macular Edema Vastly Undertreated, Real-World Data Suggest  Medscape

Most patients with newly diagnosed diabetic macular edema are inadequately treated, according to findings from the American Academy of Ophthalmology's ...

Diabetic retinopathy position statement promotes prevention, early detection, control  Healio

A new position statement by the American Diabetes Association recommends intensive glycemic control and regular screening for prevention and early ...

Kodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with Diabetic Macular Edema Demonstrating Safety and Durability of Responses Following Single Dose of Intravitreal Anti-VEGF Antibody Biopolymer Conjugate  PRNewswire

PALO ALTO, Calif., Dec. 21, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel...

Aerpio Pharmaceuticals Study for Diabetic Retinopathy Does Not Meet Endpoints  dLife.com

Aerpio Pharmaceuticals, a company focused on developing drugs to treat ocular diseases and diabetic complications, today announced top-line results from a ...

Anti-VEGF injections may play increasing role in treatment of diabetic retinopathy  Healio

Ocular Surgery News | Patients with diabetic macular edema and moderately severe to severe nonproliferative diabetic retinopathy, as determined on the ...

Diet Soda Linked to Increased Risk for Diabetic Retinopathy  Medscape

Diet soda, but not regular soda, was linked to increased risk for proliferative diabetic retinopathy, a study found; further studies are needed to confirm these ...

Eyeing Improvement: Fine-Tuning Anti-VEGF for Macular Degeneration  MD Magazine

Anti-VEGF injection therapy is the proven choice of care for AMD and DME. Still, concerns about dosing, costs, and convenience persist into 2019.

Do Corticosteroids Improve Diabetic Macular Edema Outcomes?  Medscape

Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 ...

Eylea outperforms Avastin for diabetic macular edema with moderate or worse vision loss  National Institutes of Health

A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug ...

Light Mask to Inhibit Dark Adaptation Does Not Prevent Diabetic Macular Edema Progression  Endocrinology Advisor

The CLEOPATRA study provides evidence that the light mask offered to prevent dark adaptation is not recommended as a treatment option for ...

Diet soda consumption associated with increased risk of diabetic retinopathy  Healio

Researchers found that patients with diabetes who consumed more than four cans per week of a diet soft drink had a more-than-twofold risk of having ...

Disorganization of Retinal Inner Layers Linked to Visual Acuity Prognoses  MD Magazine

A new study suggests patients with disorganized retinal inner layers see lesser levels of visual acuity improvement after therapy.

» Load more